IL28B genetic variation and ratio of y-GT/ALT as predictors for virological response in chronic hepatitis C virus genotype 1 infected patients

Introduction: Chronic hepatitis C virus (HCV) genotype 1 infection is currently treated with pegylated interferon-α and ribavirin (PEG-IFN-α/RBV). This therapy leads to successful virus eradication in about half of the patients. With regard to the upcoming directly acting antiviral drugs, predictive factors are demanded more than before to help in the decision on a standard combination or a triple therapy. Methods: This retrospective study analysed the therapy outcomes of 264 patients with chronic genotype 1 hepatitis C with regard to IL28B rs12979860 and rs8099917 genotypes and pretreatment ratio of serum γ-GT…